1Martel MK, Ten - Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3 - D dose distributions of non - small cell lung cancer patients[J ]. Lung Cancer, 1999,24:31.
2Hayman JA, Martel MK, Ten Haken R, et al. Dose escalation in non-small - cell lung cancer using three dimensional eonformal radiation therapy: update of a phase Ⅰ trial[ J ]. J Clin Oncol, 2001,19 : 127.
3Graham MV, Purdy HA, Emami B, et al. Clinical dose bolume histogram analysis for pneumonifis after 3 dimensional treatment for non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,1999,45(2) :323.
4Armstrong J, Raben A, Zelefsky M, et al. Promising survival with 3 - dimensional conformal radiaion therapy for NSCLC [ J ]. Radiot her Onacol, 1997,44 : 17.
5Sibley GS, Mundt A J, Shapiro C, et al. The treatment of stage Ⅲ non - small cell lung cancer using high dose eonformal radiotherapy[J]. Int J Radiat Oneol Biol Phys, 1995,33(5) :1001.
6Sire S, Rosenzweig KE, Sehindelheim R, et al. Intuetion chemo-therapy plus three - dimensional eonformal radiation therapy inthe definitive treatment of advanced non--small cell lung cancer[J ]. Int J Radiat Oneol boilPhys, 2001,51:660.
2Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer, 2001,31:43-56.
3Martel MK, Ten-Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of nonsmall cell lung cancer patients. Lung Cancer, 1999,24:31-37.
4Ragazzi G, Cattaneo GM, Fiorino C. Use of dose-volume histograms and biophysical models to compare 2D and 3D irradiation techniques for nonsmall cell lung cancer. Br J Radiol, 1999,72:279-288.
5Ready NE, Vokes EE.Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. Lung Cancer, 2003,42 Suppl 2: S65-69.
6Dillman RO,Hemdon J,Seagren SL,et al. Improved survival in stage Ⅲ non-small-cell lung cancer: seven-year follow-up of Cancer and Group B (CALGB)8433 trial. J Natl Cancer Inst, 1996,88:1210-1215.
7Chen LM, Ignacio L, Jacobs R, et al. Results of a phase Ⅱ concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage Ⅲ non-small-cell lung cancer.Radiat Oncol Investig, 1999,7: 49-53.
8Cheung PC, Yeung LT, Basrur V, et al. Accelerated hypofractionation for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys,2002,54:1014-1023.
9Slotman B J, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small-cell lung cancer. Radiother Oncol, 1996, 41:41-44.
6Wang Y,Shi XH.Comparison the toxicity of old people in accelerated hyperfractionated for esophageal carcinoma[J].Int J Radiat Oncol Biol Phys,2003,26 (2):26 -36.
7Withers HR,Taylor LMG,Maciejewski B.The hazard of accelerated tumor clonogen repopulation during radiotherapy[J].Acta Oncol,1988,27(2):131-146.
